- Home
- MFA vs NUVB Comparison
MFA vs NUVB Comparison
Compare MFA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- NUVB
- Stock Information
- Founded
- MFA 1997
- NUVB 2018
- Country
- MFA United States
- NUVB United States
- Employees
- MFA N/A
- NUVB N/A
- Industry
- MFA Real Estate Investment Trusts
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- NUVB Health Care
- Exchange
- MFA Nasdaq
- NUVB Nasdaq
- Market Cap
- MFA 980.3M
- NUVB 837.0M
- IPO Year
- MFA N/A
- NUVB N/A
- Fundamental
- Price
- MFA $10.10
- NUVB $2.91
- Analyst Decision
- MFA Buy
- NUVB Strong Buy
- Analyst Count
- MFA 8
- NUVB 6
- Target Price
- MFA $11.43
- NUVB $8.00
- AVG Volume (30 Days)
- MFA 1.3M
- NUVB 4.7M
- Earning Date
- MFA 08-06-2025
- NUVB 08-07-2025
- Dividend Yield
- MFA 14.27%
- NUVB N/A
- EPS Growth
- MFA 41.64
- NUVB N/A
- EPS
- MFA 0.88
- NUVB N/A
- Revenue
- MFA $284,489,000.00
- NUVB $14,355,000.00
- Revenue This Year
- MFA N/A
- NUVB $332.80
- Revenue Next Year
- MFA $12.27
- NUVB $360.12
- P/E Ratio
- MFA $11.46
- NUVB N/A
- Revenue Growth
- MFA 9.37
- NUVB 900.35
- 52 Week Low
- MFA $7.85
- NUVB $1.54
- 52 Week High
- MFA $13.45
- NUVB $3.46
- Technical
- Relative Strength Index (RSI)
- MFA 65.95
- NUVB 66.89
- Support Level
- MFA $9.68
- NUVB $2.57
- Resistance Level
- MFA $9.93
- NUVB $2.55
- Average True Range (ATR)
- MFA 0.22
- NUVB 0.20
- MACD
- MFA 0.07
- NUVB 0.03
- Stochastic Oscillator
- MFA 97.77
- NUVB 90.62
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.